



Joris VANDEPUTTE

Former President of IABS
Board member of Actors4Health
France

Dr. Veterinary Medicine, virologist, global experience and network in human and animal health, vaccines and diagnostics, global disease control, one health, public affairs with EU, WHO, Asian and African authorities.

Experienced in translational development, translating proof of concept into products (quality, regulatory, profiling, logistics and market access).

Main achievements in virology and global vaccine development:

- Discovery of H1N1 in the late 70's, proof of swine in the zoonotic chain of flu (University Research)
- Development, production, flu vaccines (Rhône Mérieux, Merial)
- Global vaccine development, production, successful marketing vaccines for viral and bacterial diseases in animals (Rhône Mérieux, Merial)
- Development of TB vaccines for humans (TBVI)
- COVID-19: virology and vaccination, focus on platform technologies and pre-clinical experiments
- Platform technologies for human and animal vaccines and antibodies (mRNA, DNA, viral vectors, Scaffold particles): research, development, CMC, production and regulatory (Vaccines by design)
- In vitro testing for batch release (quality control by design)

Main achievements in global networking and with EU institutions:

- GAVI Alliance and the Vaccine Fund: part of GAVI, Vaccine Fund 2001-2005/ successful EU support
- GALVMED: successful funding for African vaccine development for livestock VACNADA (Vaccines for PPR, Newcastle, CCPP and CBPP)
- Tuberculosis vaccines for humans: EU support for TBVI (resolution of the EU Parliament)
- Vaccine and antibody platform technologies translation in EU regulation (2019/06), for surge production and pandemic preparedness
- IMI (Innovative Medicines Initiative) EU and HORIZON EUROPE projects: work package leader in Zoonosis Anticipation Preparedness Initiative (ZAPI) and VAC2VAC (Vaccine batch to batch comparison by consistency testing); participant in IMI projects DRIVE (Influenza Vaccine Effectiveness) and Inno4Vacc (Controlled Human Challenges), Work package leader in HORIZON 2020 project MANCO (Monoclonal antibody development against SARS-CoV-2)

President of IABS (International Alliance for Biological Standardization) 2016-2022.

Member of the Scientific Advisory Board of the World Vaccine Congress

Quadrilingual: Dutch, French, English, German

Latest publications and communications:

- February 16 – 17 2023 co-organizer of the symposium Enabling the Evaluation of COVID-19 Vaccines with Correlates of Protection

- The consistency approach for the substitution of in vivo testing for the quality control of established vaccines: practical considerations and progressive vision, Jean-Francois Dierick, Marlies Halder, Carmen Jungbaeck, Julie Lorenz, Jean-Marie Préaud, Patrice Riou, Lorenzo Tesolin, Sylvie Uhlrich, Wim Van Molle, Joris Vandeputte, *Open Research Europe* 2022, 2:116 Last updated: 05 January 2023
- Accelerating Global Deletion of the Abnormal Toxicity Test for vaccines and biologicals. Planning common next steps. A workshop Report. Laura Viviani; Kirsty Reid; Thierry Gastineau; Catherine Milne; Dean Smith; Robin Levis; Dianliang Lei; Mark van Ooij; Philippe Alexandre Gilbert; Joris Vandeputte; et al/ *Biologicals*, June 28, 2022.
- Panel leader, World Vaccine Congress, October 2022, 11-14, on platform technologies
- Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development? J. Vandeputte, P. Van Damme, J. Neyts, J.C. Audonnet, M. Baay, P. Neels, *BIOLOGICALS*, 2021, <https://doi.org/10.1016/j.biologicals.2021.08.001>
- IABS/CEPI platform technology webinar: Is it possible to reduce vaccine development time, Joris Vandeputte, Melanie Saville, Marco Cavaleri, Martin Friede, Adam Hacker, Stefan O. Mueller, Ruber Rizzi, Dean Smith, Steffen Thirstrup, Ralf Wagner, Marc Baay, Pieter Neels, *BIOLOGICALS*, 2021, <https://doi.org/10.1016/j.biologicals.2021.04.005>
- Pandemic Preparedness, Global Health Press, May 2023, *VacciTUTOR* Chapter 2